|
Friday 29th November 2024 |
Text too small? |
Rua Bioscience is pleased to annouce the release of our newest dried flower product, marking another significant milestone for the company. This is the second flower product launched by Rua in New Zealand in the last six months, reflecting our ongoing efforts to grow our portfolio in our home market of Aotearoa New Zealand.
This new product has already generated significant demand ahead of its release, and Rua expects market uptake to be strong.
The New Zealand market, along with our other key markets, is still showing evidence of substantial growth. The market more than doubled in size between FY23 and FY24 which suggests greater acceptance by Doctors, Pharmacists and Patients.
[GRAPH IN ATTACHMENT]
As part of our dedication to supporting equitable access to medicines, this product will also be included in Compassionate Access Programme. This initiative reflects our commitment to redcuing barriers to access for those paitents least able to afford this medicine.
Paul Naske, CEO of Rua Bioscience says “Whilst we are focused on large export markets, this launch is testament to our connection to Aotearoa New Zealand. We’re immensly proud to bring another product to our home market”.
This significant achievement reflects Rua’s continued focus on sales and revenue growth and our commitment to delivering for the people and communities of Aotearoa New Zealand.
ENDS
No comments yet
IFT - Infratil Full Year Results for the year ended 31 March 2026
May 27th Morning Report
RYM - FY26 marks significant year of progress
FPH reports strong revenue and profit growth for FY26
IFT - Infratil Full Year Results for the year ended 31 March 2026
PEB - Advancing Medicare Coverage Goals; Cost Contained
TRU - TruScreen Completes Oversubscribed Placement
EROAD Continues Transformation, Reports FY26 Results
May 25th Morning Report
EROAD Appoints New Director Progressing Board Renewal